Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes
Differentiation between lethal and non-lethal prostate cancer subtypes has become a very important issue in avoiding excessive treatment in an era when prostate-specific antigen (PSA) screening has reduced the rate of prostate cancer deaths by more than 20%. However, it is difficult to determine the...
Gespeichert in:
| Veröffentlicht in: | Asian journal of andrology 2012-05, Vol.14 (3), p.361-364 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 364 |
|---|---|
| container_issue | 3 |
| container_start_page | 361 |
| container_title | Asian journal of andrology |
| container_volume | 14 |
| creator | Kakehi, Yoshiyuki |
| description | Differentiation between lethal and non-lethal prostate cancer subtypes has become a very important issue in avoiding excessive treatment in an era when prostate-specific antigen (PSA) screening has reduced the rate of prostate cancer deaths by more than 20%. However, it is difficult to determine the patients who may or may not benefit from immediate treatment interventions at the time of the initial diagnosis. The selection of candidate patients who can postpone immediate treatment and undergo follow-ups with a specific surveillance program, or 'active surveillance,' is a practical way to minimize overtreatment. In this review, the benefits and risks of active surveillance are discussed. Future perspectives, including imaging and new biomarkers for improving the outcomes of active surveillance programs, are also discussed. |
| doi_str_mv | 10.1038/aja.2011.151 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3720161</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2661246891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-a7cb121557d552a076feb4919a2c2593be5084113161c1a5def6b5a832996dc23</originalsourceid><addsrcrecordid>eNpdkc1r3DAQxUVpaD5vPRdBLz3EG41kyfalEEKTFgK5JJCbGMvjxFuv7Urywv73lck2NDnp4_14zLzH2GcQKxCqvMA1rqQAWIGGD-wIilxnhTTyY7oLUWamlI-H7DiEtRBSQVV9YodSapGXhTpivy9d7LbEw-y31PU9Do44Bo588pgkhz0P0WOkpx2PI2-6tiVPQ-zSF-8pPicAh4YP45Dtn5MfQ1xkt7j55F3H3UThlB202Ac6258n7OH6x_3Vz-z27ubX1eVt5vKijBkWrgYJWheN1hJFYVqq8woqlE7qStWkRZkDKDDgAHVDrak1lkpWlWmcVCfs-4vvNNcbalya1mNvJ99t0O_siJ19qwzds30at1YVKUgDyeDb3sCPf2YK0W664GhJh8Y5WEhxl1ooUAn9-g5dj7Mf0noLpYzRlRGJOn-hXIomeGpfhwFhlxZtatEuLdrUYsK__L_AK_yvNvUXZrOZvg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1013665960</pqid></control><display><type>article</type><title>Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Kakehi, Yoshiyuki</creator><creatorcontrib>Kakehi, Yoshiyuki</creatorcontrib><description>Differentiation between lethal and non-lethal prostate cancer subtypes has become a very important issue in avoiding excessive treatment in an era when prostate-specific antigen (PSA) screening has reduced the rate of prostate cancer deaths by more than 20%. However, it is difficult to determine the patients who may or may not benefit from immediate treatment interventions at the time of the initial diagnosis. The selection of candidate patients who can postpone immediate treatment and undergo follow-ups with a specific surveillance program, or 'active surveillance,' is a practical way to minimize overtreatment. In this review, the benefits and risks of active surveillance are discussed. Future perspectives, including imaging and new biomarkers for improving the outcomes of active surveillance programs, are also discussed.</description><identifier>ISSN: 1008-682X</identifier><identifier>EISSN: 1745-7262</identifier><identifier>DOI: 10.1038/aja.2011.151</identifier><identifier>PMID: 22504873</identifier><language>eng</language><publisher>China: Medknow Publications & Media Pvt. Ltd</publisher><subject>Diagnosis, Differential ; Disease Progression ; Humans ; Male ; Prostatic Neoplasms - classification ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - mortality ; Review ; Risk Assessment ; Sentinel Surveillance ; Unnecessary Procedures ; Watchful Waiting - methods</subject><ispartof>Asian journal of andrology, 2012-05, Vol.14 (3), p.361-364</ispartof><rights>Copyright Nature Publishing Group May 2012</rights><rights>Copyright © 2012 SIMM & SJTU 2012 SIMM & SJTU</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-a7cb121557d552a076feb4919a2c2593be5084113161c1a5def6b5a832996dc23</citedby><cites>FETCH-LOGICAL-c478t-a7cb121557d552a076feb4919a2c2593be5084113161c1a5def6b5a832996dc23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720161/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720161/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22504873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kakehi, Yoshiyuki</creatorcontrib><title>Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes</title><title>Asian journal of andrology</title><addtitle>Asian J Androl</addtitle><description>Differentiation between lethal and non-lethal prostate cancer subtypes has become a very important issue in avoiding excessive treatment in an era when prostate-specific antigen (PSA) screening has reduced the rate of prostate cancer deaths by more than 20%. However, it is difficult to determine the patients who may or may not benefit from immediate treatment interventions at the time of the initial diagnosis. The selection of candidate patients who can postpone immediate treatment and undergo follow-ups with a specific surveillance program, or 'active surveillance,' is a practical way to minimize overtreatment. In this review, the benefits and risks of active surveillance are discussed. Future perspectives, including imaging and new biomarkers for improving the outcomes of active surveillance programs, are also discussed.</description><subject>Diagnosis, Differential</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Male</subject><subject>Prostatic Neoplasms - classification</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Review</subject><subject>Risk Assessment</subject><subject>Sentinel Surveillance</subject><subject>Unnecessary Procedures</subject><subject>Watchful Waiting - methods</subject><issn>1008-682X</issn><issn>1745-7262</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkc1r3DAQxUVpaD5vPRdBLz3EG41kyfalEEKTFgK5JJCbGMvjxFuv7Urywv73lck2NDnp4_14zLzH2GcQKxCqvMA1rqQAWIGGD-wIilxnhTTyY7oLUWamlI-H7DiEtRBSQVV9YodSapGXhTpivy9d7LbEw-y31PU9Do44Bo588pgkhz0P0WOkpx2PI2-6tiVPQ-zSF-8pPicAh4YP45Dtn5MfQ1xkt7j55F3H3UThlB202Ac6258n7OH6x_3Vz-z27ubX1eVt5vKijBkWrgYJWheN1hJFYVqq8woqlE7qStWkRZkDKDDgAHVDrak1lkpWlWmcVCfs-4vvNNcbalya1mNvJ99t0O_siJ19qwzds30at1YVKUgDyeDb3sCPf2YK0W664GhJh8Y5WEhxl1ooUAn9-g5dj7Mf0noLpYzRlRGJOn-hXIomeGpfhwFhlxZtatEuLdrUYsK__L_AK_yvNvUXZrOZvg</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Kakehi, Yoshiyuki</creator><general>Medknow Publications & Media Pvt. Ltd</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120501</creationdate><title>Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes</title><author>Kakehi, Yoshiyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-a7cb121557d552a076feb4919a2c2593be5084113161c1a5def6b5a832996dc23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Diagnosis, Differential</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Male</topic><topic>Prostatic Neoplasms - classification</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Review</topic><topic>Risk Assessment</topic><topic>Sentinel Surveillance</topic><topic>Unnecessary Procedures</topic><topic>Watchful Waiting - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kakehi, Yoshiyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asian journal of andrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kakehi, Yoshiyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes</atitle><jtitle>Asian journal of andrology</jtitle><addtitle>Asian J Androl</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>14</volume><issue>3</issue><spage>361</spage><epage>364</epage><pages>361-364</pages><issn>1008-682X</issn><eissn>1745-7262</eissn><abstract>Differentiation between lethal and non-lethal prostate cancer subtypes has become a very important issue in avoiding excessive treatment in an era when prostate-specific antigen (PSA) screening has reduced the rate of prostate cancer deaths by more than 20%. However, it is difficult to determine the patients who may or may not benefit from immediate treatment interventions at the time of the initial diagnosis. The selection of candidate patients who can postpone immediate treatment and undergo follow-ups with a specific surveillance program, or 'active surveillance,' is a practical way to minimize overtreatment. In this review, the benefits and risks of active surveillance are discussed. Future perspectives, including imaging and new biomarkers for improving the outcomes of active surveillance programs, are also discussed.</abstract><cop>China</cop><pub>Medknow Publications & Media Pvt. Ltd</pub><pmid>22504873</pmid><doi>10.1038/aja.2011.151</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1008-682X |
| ispartof | Asian journal of andrology, 2012-05, Vol.14 (3), p.361-364 |
| issn | 1008-682X 1745-7262 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3720161 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Diagnosis, Differential Disease Progression Humans Male Prostatic Neoplasms - classification Prostatic Neoplasms - diagnosis Prostatic Neoplasms - mortality Review Risk Assessment Sentinel Surveillance Unnecessary Procedures Watchful Waiting - methods |
| title | Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T12%3A02%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Active%20surveillance%20as%20a%20practical%20strategy%20to%20differentiate%20lethal%20and%20non-lethal%20prostate%20cancer%20subtypes&rft.jtitle=Asian%20journal%20of%20andrology&rft.au=Kakehi,%20Yoshiyuki&rft.date=2012-05-01&rft.volume=14&rft.issue=3&rft.spage=361&rft.epage=364&rft.pages=361-364&rft.issn=1008-682X&rft.eissn=1745-7262&rft_id=info:doi/10.1038/aja.2011.151&rft_dat=%3Cproquest_pubme%3E2661246891%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1013665960&rft_id=info:pmid/22504873&rfr_iscdi=true |